Whether that transparency extends to full label disclosure is a question a direct email to [email protected] can answer before any spending happens
Lancet 1998;351:637-41
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
GLP-1 RA Cohort The median duration of the initial exposure was 3.2 months, and at the index date GLP-1 RA was most prescribed as an add-on therapy (53.4%), most often to an ACEi/ARB (52.7%) (Table 2, Supplemental Fig
The risk is highest in the year after measurement, which fits disease that is already present
However, these drugs are challenged with long-term effectiveness, as most patients taking Semaglutide regain two-thirds of their lost weight after one year of withdrawal (Wilding et al
